Leerink Partnrs Weighs in on Exact Sciences Q2 Earnings

Exact Sciences Co. (NASDAQ:EXAS) – Stock analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for Exact Sciences in a report issued on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.03 per share for the quarter, up from their prior estimate of $0.02. The consensus estimate for Exact Sciences’ current full-year earnings is ($1.13) per share.

A number of other analysts also recently commented on the stock. Evercore ISI dropped their price target on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Bank of America cut their target price on Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Stifel Nicolaus dropped their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Jefferies Financial Group upped their price objective on Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $72.94.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $57.10 on Wednesday. The stock has a market cap of $10.57 billion, a P/E ratio of -48.80 and a beta of 1.24. The firm’s 50-day simple moving average is $58.61 and its 200 day simple moving average is $58.59. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The business had revenue of $708.66 million for the quarter, compared to the consensus estimate of $716.80 million. The firm’s quarterly revenue was up 12.8% on a year-over-year basis.

Insider Activity at Exact Sciences

In other news, CEO Kevin T. Conroy bought 19,500 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. This trade represents a 1.85 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EXAS. William Blair Investment Management LLC acquired a new stake in Exact Sciences during the 2nd quarter worth about $163,896,000. Groupama Asset Managment acquired a new stake in shares of Exact Sciences during the third quarter worth approximately $821,000. Sculptor Capital LP acquired a new stake in shares of Exact Sciences during the second quarter worth approximately $32,819,000. Samlyn Capital LLC acquired a new position in Exact Sciences in the 2nd quarter valued at approximately $30,426,000. Finally, Armistice Capital LLC lifted its position in Exact Sciences by 91.6% in the 2nd quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock worth $59,154,000 after buying an additional 669,438 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.